KZR Analyst Ratings

Kezar Life Sciences, Inc. (KZR) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $53.9M, listed on NASDAQ, employing roughly 55 people, carrying a beta of 0.41 to the broader market. Kezar Life Sciences, Inc. Led by Christopher J. Kirk, public since 2018-06-21.

Price Targets

Average Target

$11.00

High

$21.00

Low

$5.00

Recent Upgrades & Downgrades

How to Read KZR Analyst Coverage

Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.

For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.

Learn how analyst ratings is reported and how to read the data →